top of page
Picture.png

Unleashing the true potential of immuno-oncology.

Technology

Multi-Pathway Immune Engager Nanofilaments 

TATUM Bioscience is redefining cancer treatment with nanofilament immunotherapy. Our breakthrough technology boosts tumor visibility, restores immune function, and drives lasting antitumor responses—positioning TATUM at the forefront of next-generation immuno-oncology.

(NC) 1 oct Démonte ton mythe QC_edited.png
Technology 1.png

Nanofilaments are injected
intratumorally

Our technology

Team

Management 

AI5A1921.jpg

Jean-François Millau, PhD

CEO and co-founder

  • LinkedIn
AI5A2356.jpg

Kevin Neil, PhD

CSO and co-founder

  • LinkedIn
Veronique.jpg

Veronique Riethuisen, MSc

CFO

  • LinkedIn
Alexandre.jpg

Alexandre LeBeaut, MD

CMO

  • LinkedIn

Board members

Jacques.jpg

Jacques Dessureault, MSc, C.Dir., CCA

Chairman of the board

  • LinkedIn
AI5A1921.jpg

Jean-François Millau, PhD

CEO TATUM bioscience

  • LinkedIn
marc Rivière.jpg

Marc Rivière, MD

General Partner and CMO at TVM Capital

  • LinkedIn
rebecca.jpg

Rebecca Allan, PhD

Investment Manager Life Sciences at BoxOne Venture

  • LinkedIn
Jesse.jpg

Jesse Paterson, MSc

Senior Director Business Development at CQDM

  • LinkedIn
Contact

Let's get in touch

For general inquiries contact us at: ​​​

info_tatumbio.com.png

To become a TATUMer and join the team send your motivation letter at: 

jobs_tatumbio.com.png

Thank you for contacting us!

TATUM bioscience is proudly supported by:

BoxOne - Investor.png
ACET accelerator.png
SCBio-Drive- Accelerator.png
CBV Accelerator.png
SHERBROOKE-INNOVANTE-POSITIF-RVB.png
adMare Accelerator.png
creative-destruction-lab Accelerator.png
cqdm Investor.png
MaRS Accelerator.png
IQ Investor.png

©2025 TATUM Bioscience Inc. Background image by Design Cell.

bottom of page